Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 12/20 | 0.43 |
| ▸ | MAP3K8 | P41279 | 11/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431422 | 1.00 | STK17B (0.43) | STK17BMAP3K8STK17A | |
| SCHEMBL4420334 | 0.80 | STK17B (0.40) | STK17BMAP3K8STK17A | |
| SCHEMBL4417588 | 0.79 | IKBKB (0.46) | STK17BMAP3K8STK17A | |
| SCHEMBL4417586 | 0.79 | IKBKB (0.46) | STK17BMAP3K8STK17A | |
| SCHEMBL4422587 | 0.77 | MAPK1 (0.35) | MAP3K8 | |
| SCHEMBL4422583 | 0.77 | MAPK1 (0.35) | MAP3K8 | |
| SCHEMBL4419732 | 0.67 | EGFR (0.38) | — | |
| Hydrochloric Acid SCHEMBL4432013 | 0.66 | EGFR (0.37) | — | |
| Hydrochloric Acid SCHEMBL4432011 | 0.66 | EGFR (0.37) | — | |
| SCHEMBL6781682 | 0.66 | AURKA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-1272185-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | STK17B 3419/4885MAP3K8 4175/4885STK17A 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.